Cargando…
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%–10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchic...
Autores principales: | Kacar, Mark, Savic, Sinisa, van der Hilst, Jeroen C H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069573/ https://www.ncbi.nlm.nih.gov/pubmed/32210604 http://dx.doi.org/10.2147/JIR.S206204 |
Ejemplares similares
-
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015) -
Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015) -
Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases
por: Tsinti, Maria, et al.
Publicado: (2014) -
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
por: van der Hilst, Jeroen CH, et al.
Publicado: (2016) -
The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)